EKF Diagnostics buys back 213,000 shares at 26p each
#EKF Diagnostics #Share Buyback #AIM Exchange #26p per share #Treasury Shares #Capital Management #Christopher Mills #Oryx International
📌 Key Takeaways
- EKF Diagnostics purchased 213,000 ordinary shares at 26 pence each
- The buyback consisted of two separate transactions on the AIM exchange
- The transaction involved shares from Oryx International Growth Fund and North Atlantic Smaller Companies Investment Trust
- The buyback maintained Christopher Mills' beneficial interest below 30% of voting rights
- Post-buyback, EKF holds 354,000 shares in treasury out of 431,963,112 total shares
📖 Full Retelling
EKF Diagnostics Holdings plc (AIM:EKF) purchased 213,000 of its ordinary shares on Wednesday, June 3, 2026, at a weighted average price of 26 pence per share on the AIM exchange in London, as part of the company's capital management strategy. The company executed two separate transactions on the London Stock Exchange's Alternative Investment Market (AIM), acquiring 150,000 shares at 13:12:06 and 63,000 shares at 16:41:41, both at the same price of 26 pence per share. The purchased shares will be held in treasury, which is a common practice for companies that buy back their own stock. Notably, a portion of the buyback involved 63,000 ordinary shares acquired from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. This transaction comprised 21,000 shares from Oryx and 42,000 shares from NASCIT. Harwood facilitated this specific transaction to ensure that Christopher Mills, a non-executive director, maintained his aggregate indirect beneficial interest at approximately the same level and did not exceed 30% of total voting rights following the repurchases. After this share sale, Mills' aggregate indirect interest in the company stands at 127,277,000 ordinary shares. In terms of the company's capital structure, after the purchase, EKF's total issued share capital consists of 431,963,112 ordinary shares, of which 354,000 shares are held in treasury. The total number of ordinary shares carrying voting rights is 431,609,112. EKF Diagnostics is a global diagnostics business with a focus on point-of-care analyzers in hematology and diabetes, as well as life sciences services. The company operates five manufacturing sites across the United States and Germany, selling its products into over 120 countries worldwide.
🏷️ Themes
Corporate Finance, Stock Market, Diagnostics Industry
📚 Related People & Topics
Share repurchase
Reacquisition by a company of its own shares
Share repurchase, also known as share buyback or stock buyback, is the reacquisition by a company of its own shares. It is an alternative way of returning money to shareholders than dividends. After a repurchase event, the company's stock price is now proportionally higher because of the smaller num...
EKF Diagnostics
EKF Diagnostics (Entwicklung, Konstruktion und Fertigung) is a publicly listed Healthcare company founded 1990 in Barleben, Germany and currently headquartered in Cardiff, Wales, UK. EKF Diagnostics specialises in the development, manufacture and distribution of point of care analysers for hemoglobi...
Entity Intersection Graph
Connections for Share repurchase:
🌐
London Stock Exchange
6 shared
🌐
Corporate finance
6 shared
🌐
Stock market
3 shared
🏢
Dividend
2 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil holds steady after 5-day winning streak; set for weekly surge on Iran conflict Trump replaces Homeland Security chief Kristi Noem Gold rises but heads for weekly loss as firm dollar dulls haven appeal Wall Street ends lower on escalating Iran conflict, report of AI export curbs (South Africa Philippines Nigeria) EKF Diagnostics buys back 213,000 shares at 26p each By Company News Published 03/06/2026, 02:27 AM EKF Diagnostics buys back 213,000 shares at 26p each 0 EKF -3.52% LONDON - EKF Diagnostics Holdings plc (AIM:EKF) purchased 213,000 of its ordinary shares on Wednesday at a weighted average price of 26 pence per share, according to a press release statement. The company executed two transactions on the AIM exchange, acquiring 150,000 shares at 13:12:06 and 63,000 shares at 16:41:41, both at 26 pence per share. The purchased shares will be held in treasury. As part of the buyback, EKF acquired 63,000 ordinary shares from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The transaction involved 21,000 shares from Oryx and 42,000 shares from NASCIT. Harwood facilitated the transaction to ensure that the aggregate indirect beneficial interest of Christopher Mills, a non-executive director, remains at approximately the same level and does not exceed 30% of total voting rights following the repurchases. Following the share sale, Mills’ aggregate indirect interest in the company stands at 127,277,000 ordinary shares. After the purchase, EKF’s total issued share capital consists of 431,963,112 ordinary shares, of which 354,000 shares are held in treasury. The total number of ordinary shares carrying voting rights is 431,609,112. EKF Diagnostics is a global diagnostics business focused on point-of-care analyzers in hematology and diabetes, as well as life sciences services. The company operates five manufacturing sites across t...
Read full article at source